Therapeutic area intelligence for Lipid Management with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.

Signals: 2
Catalysts: 0
Companies: 1

Companies

Impax Labs →

Assets

FDA →

rosuvastatin →

Recent signals(2)

RegulatoryJuly 27, 2026

FDA Grants AP Status for Colestipol Hydrochloride Supplement by Impax Labs

The FDA has granted an Abbreviated New Drug Application (ANDA) approval status for a supplement of Colestipol Hydrochloride submitted by Impax Labs.

ClinicalJune 28, 2026

Trial Evaluates Dual vs Triple Lipid-Lowering Therapy in Type 2 Diabetes Patients

A clinical trial is underway to compare the efficacy and safety of dual versus triple lipid-lowering therapy in patients with type 2 diabetes and elevated LDL cholesterol.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

No related entities indexed yet.

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.